Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3

STATUS

Recruiting
participants needed

49
sponsor

Genzyme, a Sanofi Company

Send

Updated on 19 February 2024

See if I qualify

Summary

Primary Objectives:

Part 1:

Cohorts 1, 2 and 3

Evaluate cerebrospinal fluid (CSF) biomarkers in adult Gaucher disease (GD) Type 3 patients that distinguish GD3 from adult Gaucher disease Type 1 (GD1) patients.
Screen adult and pediatric GD3 patients who qualify for treatment with venglustat in Parts 2 and 3.

Parts 2 and 3:

Cohort 2

Evaluate short-term (Part 2) and long-term (Part 3) safety and tolerability of venglustat in combination with Cerezyme in adult GD3 patients.
Evaluate the change in CSF central nervous system (CNS) biomarkers (glucosylceramide [GL-1] and lyso-glucosylceramide [lyso-GL1]) from adult GD3 patients receiving venglustat in combination with Cerezyme (Part 2 only).

Cohort 3

Evaluate the efficacy of venglustat in combination with Cerezyme in adult and pediatric GD3 patients by assessing:
Ataxia using the Scale for the Assessment and Rating of Ataxia (SARA)
Cognition using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

Secondary Objectives:

Parts 2 and 3:

Cohort 2

Evaluate the pharmacokinetics (PK) of venglustat in adult GD3 patients.

Cohort 3

Evaluate the efficacy of venglustat in combination with Cerezyme in adult and pediatric GD3 patients by assessing:
CSF Lyso-GL1 levels
Modified Friedreichs Ataxia Rating Scale - Activities of Daily Living (FARS-ADL)
Brain resting-state functional Magnetic Resonance Imaging (rs-fMRI) reflecting connectivity between parieto-occipital areas
Bone disease manifestations
Evaluate safety and tolerability of venglustat in combination with Cerezyme in adult and pediatric GD3 patients
Evaluate PK of venglustat in adult and pediatric GD3 patients.

Description

The total duration for GD1 participants is 45 days (Part 1), while for GD3 participants the total duration is up to 4.2 years for Cohort 2 and up to 3.7 years for Cohort 3.

Details

Condition	Gaucher Disease Type 1-Gaucher Disease Type 3, Gaucher Disease Type 1-Gaucher Disease Type 3
Age	12years - 100years
Treatment	Placebo, venglustat (GZ/SAR402671), imiglucerase
Clinical Study Identifier	NCT02843035
Sponsor	Genzyme, a Sanofi Company
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	For participants 18 years of age: Participant must provide written informed consent prior to any study-related procedures being performed
	For participants 12 and <18 years of age: Parent(s)/legal guardian(s) must provide written informed consent prior to any study related procedures being performed. If the patient is considered able by local regulation, assent will also be obtained before any study related procedures are performed
	Participant has a clinical diagnosis of Gaucher Disease Type 1 (GD1) or Gaucher Disease Type 3 (GD3) and documented deficiency of acid beta-glucosidase activity confirming this diagnosis
	Participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months and is within the therapeutic goals defined below, and is deemed clinically stable for at least 1 year by the Investigator
	Participant has reached Gaucher disease therapeutic goals defined as all of the
	following
	Hemoglobin level of 11.0 g/dL for females and 12.0 g/dL for males
	Platelet count 100,000/mm3
	Spleen volume <10 multiples of normal (MN), or total splenectomy (provided the splenectomy occurred >3 years prior to randomization)
	Liver volume <1.5 MN
	No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening
	Participant, if female and of childbearing potential, must have a negative pregnancy test [urine beta-human chorionic gonadotropin (-hCG)] at baseline
	If participant has a history of seizures, except for myoclonic seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of cytochrome P450 (CYP) 3A
	Participant is willing to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for 72 hours prior to administration of the first dose of venglustat and for the duration of the treatment period
	Oculomotor apraxia characterized by a horizontal saccade abnormality
	Female participants of childbearing potential and male patients must be willing to practice true abstinence in line with their preferred and usual lifestyle, or use 2 acceptable effective methods of contraception for the duration of the study and for at least 6 weeks for females and 90 days for males following their last dose of venglustat
	Cohort 1 only
	GD1 participant is 18 and 40 years of age
	Cohort 2 only
	GD3 participant is 18 years of age
	Cohort 3 only
	GD3 adult participant 18 years of age
	GD3 pediatric participant is 12 years of age <18 years and 30 kg of weight. For male patients 12 to <18 years of age: There is a potential risk for venglustat to impact male fertility particularly when used in patients who have not reached a certain stage of sexual maturation. If a patient has not reached Tanner Stage 3 by the screening visit, the Investigator should assess and discuss with the patient the potential benefits and risks when considering eligibility for study participation. In this benefit/risk assessment-discussion, the parent(s)/legal guardian(s), the patient (if considered able by local regulation), and the Sponsor's medical representative (if considered appropriate) shall be consulted
Exclusion Criteria
	Substrate reduction therapy or chaperone therapy for GD within 6 months prior to enrollment
	Participant has had a partial or total splenectomy within 3 years prior to randomization
	Participant is blood transfusion-dependent
	Prior esophageal varices or liver infarction or current liver enzymes (alanine aminotransferase [ALT]/ aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal, unless the patient has a diagnosis of Gilbert Syndrome
	Participant has any clinically significant disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation
	Participant has renal insufficiency, as defined by an estimated glomerular filtration rate <30 mL/min/1.73m2 at the screening visit
	Participant has received an investigational product within 30 days prior to enrollment
	Participant has a history of cancer, with the exception of basal cell carcinoma
	Participant has myoclonic seizures
	Participant is pregnant or lactating
	Participant has, according to World Health Organization (WHO) Grading, a cortical cataract >one-quarter of the lens circumference (Grade cortical cataract-2) or a posterior subcapsular cataract >2 mm (Grade posterior subcapsular cataract-2). Patients with nuclear cataracts will not be excluded
	Participant requires use of invasive ventilatory support
	Participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily
	Participant is unable to receive treatment with Cerezyme due to a known hypersensitivity or is unwilling to receive Cerezyme treatment to ensure maintenance of Gaucher treatment goals
	Participant is currently receiving potentially cataractogenic medications (corticosteroids, psoralens used in dermatology with ultraviolet light therapy [PUVA], typical antipsychotics, and glaucoma medications) or any medication that may worsen the vision of a patient with cataract (eg, alpha-adrenergic glaucoma medications)
	Participant has received strong or moderate inducers or inhibitors of CYP3A within 15 days or 5 half-lives from screening, whichever is longer, prior to enrolment in Part 2\. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat administration in Parts 2 and 3
	Participant is scheduled for in-patient hospitalization including elective surgery, during the study
	Participant has had a major organ transplant (e.g., bone marrow or liver)
	Participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (e.g., contraindications for magnetic resonance imaging)
	The above information is not intended to contain all considerations relevant
	to a patient's potential participation in a clinical trial

How to participate?

Step 1 Connect with a study center

Send a message

Enter your contact details to connect with study team

First name*

Last name*

Email*

Phone number*

Other language

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Venglustat in Combination With Cerezyme in Adult and Pediatric Patients With Gaucher Disease Type 3